D57.438
Sickle-cell thalassemia beta zero with crisis with other specified complication
Clinical Classification Guidelines
Use Additional Code
- code to identify complications, such as:
- cholelithiasis (K80.-)
- priapism (N48.32)
Inclusion Terms
- HbS-beta zero with other specified complication
- Sickle-cell beta zero with other specified complication
Medical Intelligence & Overview
Sickle-cell thalassemia beta zero with crisis is a complex inherited blood disorder characterized by abnormal hemoglobin production, leading to distorted (sickled) red blood cells. These misshapen cells can cause blockages in blood flow and result in various health complications. The condition often presents with episodes called crises, which can be severe and require immediate medical attention. The specific ICD-10 code D57.438 is used to classify cases involving sickle-cell beta zero thalassemia with crisis and additional specified complications, highlighting the medical community’s focus on detailed diagnosis and treatment planning.
Causes & Symptoms
Clinical Causes: Inherited genetic mutation affecting hemoglobin production Combination of sickle-cell gene (HbS) and beta-zero thalassemia gene Inheritance from both parents who carry respective genetic traits Genetic variations leading to the absence of beta-globin chain production Increased likelihood of complications due to complex genetic inheritance
Key Symptoms: Severe episodes of pain, often called sickle-cell crises Fatigue and weakness due to anemia Swelling in hands and feet Frequent infections Delayed growth and puberty in children Jaundice (yellowing of the skin and eyes) Chest pain and shortness of breath Painful swelling of the abdomen and joints Vision problems due to blocked small blood vessels
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves a combination of blood tests and genetic analysis. Common diagnostic approaches include: - Hemoglobin electrophoresis to determine the types and proportions of hemoglobin present - Complete blood count (CBC) to assess anemia levels - Genetic testing to identify mutations associated with sickle-cell disease and beta-zero thalassemia - Blood smear microscopy to observe abnormal shape of blood cells Early and accurate diagnosis helps tailor management strategies and monitor potential complications effectively.
Treatment Protocols: Management of sickle-cell thalassemia beta zero with crisis aims to reduce symptoms and prevent complications. Treatment options include: - Pain relief during crises, often with medications such as analgesics - Blood transfusions to treat severe anemia and reduce sickled cell concentration - Hydroxyurea medication to decrease the frequency of crises and improve blood flow - Antibiotics and vaccines to lower infection risk - Folic acid supplements to support red blood cell production - Bone marrow transplants may be considered in certain cases, offering potential cure - Regular monitoring and supportive care to prevent organ damage and other health issues Effective management requires a comprehensive approach with ongoing medical supervision.
Clinical Advice & FAQs
Billing Guidance
Is D57.438 a billable ICD-10 code?
Yes, D57.438 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D57.438?
Clinical documentation must specify the nature of Sickle-cell thalassemia beta zero with crisis with other specified complication and any associated comorbidities for accurate reporting.
Cite this Clinical Reference